Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | CETP | P11597 | 4/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779021 | 0.87 | LPAR3 (0.48) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL14482862 | 0.83 | PPARD (0.52) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL28663420 | 0.83 | CETP (0.57) | CETPLPAR3LPAR2LPAR1 | |
| SCHEMBL2241949 | 0.83 | PPARD (0.75) | PPARDCETP | |
| SCHEMBL7636250 | 0.82 | PPARD (0.48) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL10600251 | 0.80 | CETP (0.54) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL812032 | 0.78 | CYP3A4 (0.56) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL26980275 | 0.78 | PPARD (0.56) | PPARDCETPLPAR3LPAR2LPAR1 | |
| SCHEMBL13542808 | 0.78 | — | — | |
| SCHEMBL17860960 | 0.78 | PPARD (0.41) | PPARDCETPLPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | claimed |
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-2504435-B1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10421962-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | NITTO DENKO CORP (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536343-A1 | SKIN FIBROSIS TREATMENT AGENT | Nitto Denko Corporation (JP) | 2019-09-11 | — | — | EP | disclosed |
| US-20190040385-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TARGETING P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-2504435-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | Quark Pharmaceuticals, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012078536-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | QUARK PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012044620-A2 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011163436-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
| WO-2011084193-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085056-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011072082-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011066475-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | PPARD 3946/4885CETP 4186/4885LPAR3 3223/4885 |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | HSPH1, FABP1, LRAT | PPARD 774/4885CETP 501/4885LPAR3 257/4885 |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | COL1A1, COLGALT1, COL14A1 | PPARD 2387/4885CETP 397/4885LPAR3 496/4885 |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | MMP1, TIMP3, RNASE1 | PPARD 4511/4885CETP 4055/4885LPAR3 2744/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | PPARD 420/4885CETP 545/4885LPAR3 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.